Immucell (ICCC) Cash & Equivalents (2010 - 2026)

Immucell (ICCC) has 16 years of Cash & Equivalents data on file, last reported at $3.8 million in Q4 2025.

• Quarterly Cash & Equivalents rose 1.29% year-over-year to $3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.8 million (up 1.29% YoY) and the FY2025 annual result came in at $3.8 million, up 1.29% from the prior year.
• Cash & Equivalents slipped to $3.8 million in Q4 2025, from $3.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $11.8 million in Q1 2022 to a low of $960347.0 in Q1 2024.
• A 5-year average of $5.6 million and a median of $4.2 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 86.83% — and 2025, when it soared 378.93%.
• Tracing ICCC's Cash & Equivalents over 5 years: stood at $10.2 million in 2021, then plunged by 43.14% to $5.8 million in 2022, then tumbled by 83.1% to $978741.0 in 2023, then surged by 283.99% to $3.8 million in 2024, then increased by 1.29% to $3.8 million in 2025.
• The last three Cash & Equivalents figures came in at $3.8 million (Q4 2025), $3.9 million (Q3 2025), and $6.0 million (Q2 2025), per Business Quant data.